Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Glycemic Regulation chevron_right
  • Hypothyroidism chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Prenatal Screening chevron_right

  • Specialty Program
  • Prenatal Screening chevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Parkinson's Diseasechevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Biosimilars for RA chevron_right
  • Cytokine Immunotherapy chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Access All Programs
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Stephen Ruoss, MD

    Stephen Ruoss, MD

    Clinical Chief, Pulmonary and Critical Care Medicine Division
    Department of Medicine
    Medical Director, Stanford Medical Center Respiratory Care Services, Stanford Medical Center
    Medical Director, Stanford Medical Center Transfer Center, Stanford University Medical Center
    Stanford, California


    Related Videos

    Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC? Video

    Why we do need a heightened index of suspicion for recognizing patients who may have NTM lung disease? And what have we learned about epidemiology, transmission, biofilm formation, exposure patterns, and clinical signatures for MAC?

    Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy? Video

    Although we don’t have head-to-head trial comparison data for amikacin liposome inhalation suspension vs. IV amikacin, what do data reported in the CONVERT trial teach us about whether the liposomal construct represents a preferred strategy?

    Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease? Video

    Based on the results of two recent papers, including the CONVERT trial, what have we learned about when amikacin liposome inhalation suspension should be considered in patients with MAC lung disease?

    Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease? Video

    Given the FDA approval for the amikacin liposome inhalation suspension, how do you position this formulation in the overall sequencing of anti-infective therapy for MAC lung disease?

    Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen? Video

    Based on mechanistic differences and trial results, what is the rationale for deploying amikacin liposome inhalation suspension as the dominant route in refractory MAC lung disease patients who require intensification of their antimicrobial regimen?

    What are the specific recommendations and concrete guidelines—albeit 12 years old—for treatment for MAC lung disease? Is there flexibility as far as dosing frequency? Video

    What are the specific recommendations and concrete guidelines—albeit 12 years old—for treatment for MAC lung disease? Is there flexibility as far as dosing frequency?

    How do you put together the triad of critical data sets—stability or progression of disease by spirometry, radiographic findings and symptoms/clinical fragility—to make a final determination to expose the patient to the “burden of treatment?” Video

    How do you put together the triad of critical data sets—stability or progression of disease by spirometry, radiographic findings and symptoms/clinical fragility—to make a final determination to expose the patient to the “burden of treatment?”

    What specific findings should mandate treatment and encourage the patient to embark on a course of antimicrobial therapy? How should this multi-factorial analysis evolve and how should the patient be engaged in the decision-making process? Video

    What specific findings should mandate treatment and encourage the patient to embark on a course of antimicrobial therapy? How should this multi-factorial analysis evolve and how should the patient be engaged in the decision-making process?

    How do you analyze the complex clinical, radiographic, and microbiologic data to determine whether the patient should be started on antibiotic treatment? Video

    How do you analyze the complex clinical, radiographic, and microbiologic data to determine whether the patient should be started on antibiotic treatment?

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED